Document Detail


Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience.
MedLine Citation:
PMID:  18661089     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
SUMMARY: This study evaluated the 18-month persistence with teriparatide in 5413 postmenopausal osteoporotic women who were enrolled in an education and follow-up program. Analysis showed that the persistence rate was 81.5% for women who follow the program, higher than for existing oral antiresorptive treatments. INTRODUCTION: An education and follow-up program was developed after launch of teriparatide in France in September 2004, to help women to follow the treatment. The objective of this study was to evaluate the persistence with teriparatide in postmenopausal osteoporotic women following this program. METHODS: Data about persistence are available for the period September 2004 to June 2007. Persistence is defined as the percentage of patients still on treatment at the end of the 18-month course, and it has been compared to the data provided by the French universal health insurance system. RESULTS: Since the launch of teriparatide in France in September 2004, 5413 postmenopausal women (mean age 72.3 +/- 14.5 years) with osteoporosis and vertebral fractures (mean 3.9 +/- 2) have participated in the program. The persistence rate at 15 months was 81.5%, and our analysis suggested that a majority of patients completed the 18-month treatment course. The main reason for discontinuation was adverse events (46.7%). Data of the French Universal Health Insurance suggest that the persistence may be close to 0% for women who are not in the program. CONCLUSIONS: Postmenopausal osteoporotic women treated by teriparatide and enrolled in an education and follow-up program have a high persistence rate.
Authors:
K Briot; P Ravaud; P Dargent-Molina; M Zylberman; S Liu-Leage; C Roux
Related Documents :
20841719 - Implementing openmrs for patient monitoring in an hiv/aids care and treatment program i...
1577429 - A national survey on the use of seclusion in the psychiatric treatment of children.
3788899 - The relationship of drug program environmental variables to treatment outcome.
17514069 - Assessing organizational functioning as a step toward innovation.
12841589 - Adding a more rigorous scientific agenda to the empirically supported treatment movement.
20225509 - Uzbekistan: government discontinues pilot opiate substitution therapy program.
11183279 - Cut dvt (deep vein thrombosis) treatment costs with outpatient program for low-molecula...
16956859 - Outcomes from the mount sinai social work leadership enhancement program: evaluation an...
17356179 - Using propensity scoring to estimate program-related subgroup impacts in experimental p...
Publication Detail:
Type:  Journal Article     Date:  2008-07-26
Journal Detail:
Title:  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA     Volume:  20     ISSN:  1433-2965     ISO Abbreviation:  Osteoporos Int     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-03-05     Completed Date:  2010-01-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100105     Medline TA:  Osteoporos Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  625-30     Citation Subset:  IM    
Affiliation:
Paris Descartes University, Rheumatology Department Cochin Hospital, Paris, France. karine.briot@cch.aphp.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Bone Density Conservation Agents / administration & dosage*,  adverse effects,  therapeutic use
Epidemiologic Methods
Female
France
Humans
Middle Aged
Osteoporosis, Postmenopausal / complications,  drug therapy*
Patient Compliance / statistics & numerical data*
Patient Education as Topic / methods*
Program Evaluation
Spinal Fractures / etiology,  prevention & control
Teriparatide / administration & dosage*,  adverse effects,  therapeutic use
Chemical
Reg. No./Substance:
0/Bone Density Conservation Agents; 52232-67-4/Teriparatide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association between iron overload and osteoporosis in patients with hereditary hemochromatosis.
Next Document:  Spinal extension exercises prevent natural progression of kyphosis.